Drug Ther Bull. 2006 May;44(5):37-40.
Every year in the UK, around 16,000 people die from colorectal cancer, the second commonest cause of death from cancer in the UK after lung cancer. Over half of all people with colorectal cancer eventually die of metastatic disease. While median survival has increased with optimal use of combination chemotherapy, only a small minority of patients are still alive 5 years after diagnosis of metastases. Bevacizumab (pronounced be-va-see-zoo-mab) (Avastin - Roche) and cetuximab (se-tuks-ee-mab) (Erbitux - Merck) are two new monoclonal antibodies licensed for treating patients with metastatic colorectal cancer. Here we assess their efficacy and safety.
在英国，每年约有1.6万人死于结直肠癌，这是英国仅次于肺癌的第二大常见癌症死因。所有结直肠癌患者中，超过一半最终死于转移性疾病。虽然联合化疗的优化使用使中位生存期有所延长，但在诊断为转移后5年仍存活的患者仅占少数。贝伐单抗（发音为be-va-see-zoo-mab）（阿瓦斯汀 - 罗氏公司）和西妥昔单抗（se-tuks-ee-mab）（爱必妥 - 默克公司）是两种新的单克隆抗体，已获许可用于治疗转移性结直肠癌患者。在此我们评估它们的疗效和安全性。
